With clinical data emerging and major players like Moderna pushing into trials, this is the industry’s annual checkpoint to understand what’s working, what’s challenging, and what’s next.
Why the 9th International Neoantigen Summit is the One Meeting That Mattered
- This was the only event dedicated 100% to neoantigen therapies, bringing together the global field – including attendees from Europe, Asia and North America
- This is the only place you could benchmark clinical progress across the field – with 5 talks featuring clinical data
- This was the only forum where everyone relevant were in one room – with 6+ hours of dedicated networking and over 30% being c-suite leaders in the space
In a field this niche, missing this meeting means missing the global conversation. This was your chance for face time with your peers who were also experiencing the same challenges and how some are overcoming them.
From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this was your only platform dedicated to sharing critical developments in neoantigen therapies.
Very relevant presentations, lots of new clinical data. Good opportunities to reconnect with other attendees.
Infinitopes
I was great to get updates about latest neoantigen therapeutic programmes and to get in touch with colleagues from different countries.
Andarix Pharmaceutical
Great speaker list and actual topics in the field are addressed. Room for great discussions: after session discussions but also panels and round tables. The audience has a nice size so that it is easy to connect.
Evaxion Biotech
Explore the Previous Event Guide
- Accelerating precision immunotherapy by combining bioinformatics and AI to solve neoantigen validation bottlenecks, with insights from Khosen Bio and Transgene
- Enhancing personalised cancer vaccines through real‑world clinical learnings from Evaxion’s AI‑driven neoantigen immunotherapy platform
- Advancing DNA‑encoded neoantigen vaccines to drive robust immune responses in advanced cancer patients, featuring Nykode Therapeutics
- Unlocking the dark genome to discover novel targets for affordable, multi‑valent cancer immunotherapies, with Epitopea
- Scaling personalised neoantigen peptide immunotherapy for glioblastoma by optimising development and manufacturing pathways, with YGION Biomedical
Previous Partners
Attending Companies Included
Explore Related Events
Explore the Previous Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions